Form D · Pharmaceuticals
TOTUSRX, INC.
Longmont, CO · CIK 0001717735
Offering snapshot reported Nov 29, 2018 · SEC filing
- Reported sold
- $550K Offering amount: $2M
- Investors reported
- 47 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Sep 10, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
- Reported investors0 → 47
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 29, 2018 | Amendment | $550,000 | No comparison | 47 | SEC filing |
| Sep 25, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-295310
Source: Form D, filed Nov 29, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Craig Norman Changstrom | Executive |
| Kevin Michael Conlon | Executive |
| Geoffrey Thomas Williamson | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4051 Camelot Circle
Longmont, CO, 80504
Longmont, CO, 80504